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PARENTAL THERAPY PREFERENCES FOR CHILDREN  
WITH FOOD ALLERGY 
 
MARY L. SIRACUSA 
 
ABSTRACT 
 
Background: Pediatric food allergy is increasing in prevalence, and a number of 
potential immunotherapies are being developed in an attempt to address this health issue. 
However, there have been no studies investigating parental concerns and priorities 
regarding selecting a potential immunotherapy for their child.  
Objectives: To describe parental immunotherapy preferences and the factors influencing 
those preferences.  
Methods: A survey was developed to understand parental food allergy therapy 
preferences. Cognitive interviews were performed with parents of food-allergic children 
(n = 6) to ensure the feasibility and comprehensibility of the survey. The online survey 
was then disseminated to parents of children with food allergies via social media venues 
from February 1, 2016 to March 7, 2016 (N = 246). Descriptive statistics were used to 
report and analyze the attitudes and perceptions of parents considering enrolling their 
child in a food allergy therapy.   
Results: Among parents of food-allergic children, 50% (n = 123) reported that if food 
allergy therapies were made publicly available, they would enroll their children in a 
vi 
therapy. Survey data demonstrated that 69.5% (n = 171) of participants ranked 
epicutaneous immunotherapy (EPIT) as their first choice, (22.8%, n = 56) ranked oral 
immunotherapy (OIT) as their first choice, and 7.7% (n = 19) ranked sublingual 
immunotherapy (SLIT) as their first choice. The majority of parents (62.60%, n = 154) 
cited the safety profile of a specific therapy as the principal factor influencing their 
choice of preferred immunotherapy. 
Conclusion: This study suggests that many parents would choose to enroll their children 
in a food allergy therapy if given the opportunity. The majority of parents participating in 
this study preferred EPIT to OIT and SLIT. Though comfort and efficacy are important 
factors when choosing an immunotherapy, the principal concern of participants was the 
safety profile of the therapy.  
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INTRODUCTION 
 
Food allergy is an adverse reaction of the immune system that occurs when 
exposed to a certain food (Boyce et al., 2010). In the United States, an estimated 8% of 
children have a food allergy, and evidence suggests the prevalence is gradually increasing 
(Gupta et al., 2011). Although many food-allergic reactions are mild, almost 40% of 
children with food allergy have experienced life-threatening reactions, most often with 
peanuts, tree nuts, and shellfish (Gupta et al., 2011; Lanser et al., 2015). Severe reactions 
can include respiratory, gastrointestinal, and cardiovascular system compromise, as well 
as skin and mucosal tissue symptoms. These reactions are referred to as “anaphylaxis” 
when two or more systems are affected (Welch et al., 2015). If left untreated, 
anaphylactic reactions can be fatal. Children with food allergy are also at increased risk 
for comorbid atopic conditions, such as asthma and atopic dermatitis. In addition to its 
impact on physical health, food allergy can have significant social and psychological 
effects on children and their caregivers; it is often associated with social limitations and 
impaired quality of life (Boyce et al., 2010; Gupta et al., 2011). 
Eight foods account for nearly 90% of all food allergens in the United States. 
These eight foods are peanuts, tree nuts, milk, eggs, soy, wheat, fin fish, and shellfish 
(Kulis et al., 2011). Peanut allergies are most prevalent, affecting 24.8% of children with 
food allergies (Dyer et al., 2015). The prevalence of peanut allergy has steadily increased 
over time, and patients seldom outgrow allergies to peanuts (Anagnostou et al., 2014). 
Conversely, both egg and milk allergies are frequently outgrown. 
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The diagnosis of food allergy involves the measurement of specific serum 
immunoglobulin E (IgE) levels, elimination diets, skin prick tests, and oral food 
challenges, as well as a careful study of the patient’s medical history (Sicherer et al., 
2006). The mainstay of food allergy management involves the avoidance of allergens in 
an attempt to prevent reactions. Avoidance, however, is often difficult to achieve because 
of factors such as cross-contact and hidden exposures (Sicherer et al., 2014). Food-
allergic patients at risk for anaphylaxis are encouraged to carry epinephrine auto-injectors 
to treat the symptoms of an allergic reaction (Simons et al., 2011). Antihistamines may 
also be used to ameliorate symptoms, but they are not sufficient to treat an anaphylactic 
reaction and should not be used as a replacement for epinephrine.  
The prevention of food allergy is a topic of active investigation. To date, few 
preventive strategies have proven beneficial. Current evidence suggests that maintaining 
a healthy, varied diet during pregnancy, without eliminating potential allergens, may 
reduce the risk of future food allergy in the fetus (Sicherer et al., 2014). The LEAP 
(Learning Early About Peanut) study, performed by DuToit (et al., 2015), demonstrated 
that infants exhibiting certain high risk factors for developing a peanut allergy (e.g., 
positive skin prick tests, severe eczema) benefit from early exposure to peanut. The study 
found that early and regular consumption of peanut products reduced development of 
peanut allergy among this population of children (DuToit et al., 2015). The investigators 
of this clinical trial proposed that early introduction of peanut products may elicit a 
protective immune response and that deliberate allergen avoidance may not be an 
effective strategy to impede the development of allergy. 
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Although epinephrine may be used to treat anaphylaxis in case of accidental 
exposure, there is no cure for food allergies. However, promising therapies are currently 
being studied. The goal of these studies is to desensitize patients by stimulating the 
immune system with steadily increasing doses of allergen. Eventually, patients may 
develop a tolerance for their allergen. Sustained unresponsiveness may be induced as a 
result of the therapy. This is determined by the patients’ ability to undergo an oral food 
challenge (OFC) without symptoms of an allergic reaction and to introduce the allergen 
into their diet after immunotherapy (Vickery et al., 2015).  
Of the immunotherapies being tested, significant progress has been made with 
oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous 
immunotherapy (EPIT) (Jones et al., 2014). These therapies are not currently available to 
the public but have demonstrated varying levels of effectiveness. Although multiple 
clinical trials have examined the safety and efficacy of these three potential treatments, to 
date, there has not been a study investigating the therapy preferences of participants in 
these clinical trials. 
 
Oral Immunotherapy (OIT) 
During OIT, patients ingest small doses of their food allergen, usually in the form 
of a powder, under medical supervision (Trendelenburg et al., 2014). The ingested dose is 
gradually increased over a period of time. OIT clinical trials have been performed for 
many food allergens, but the majority of studies have investigated peanut, cow’s milk, 
and egg protein. Although clinical trials have varied in method, OIT is generally 
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comprised of three phases: escalation, build-up, and maintenance (Figure 1) (Vickery et 
al., 2014).  
During the initial escalation phase, subjects ingest small amounts of allergen 
protein in a clinical setting. In many studies, this dose is increased over specific time 
increments until a maximum dose is reached. The initial escalation phase commonly 
occurs over a seven-hour period, with 30-minute dosing intervals. The patient is observed 
in clinic for a minimum of two hours after ingestion and then discharged with an 
epinephrine auto-injector. 
During the build-up phase, patients are given daily doses of their allergen. Doses 
are increased every two weeks until a maximum dose is reached. To an extent, the dosing 
and timing are at the discretion of the physician based on the patient’s reaction history, 
though a maximum dose of 5000 mg is common in many OIT trials (Vickery et al., 2014; 
Burks et al., 2012; Varshney et al., 2011). Depending on the study procedure, the build-
up phase is performed either predominantly at home, with periodic clinic visits to 
increase the dosage, or during regular clinic visits. The build-up phase generally lasts six 
to nine months.  
The maintenance phase of OIT occurs when patients are sufficiently desensitized 
to safely ingest a target dose of allergen. Patients continue to consume specific daily 
doses of their allergens, often at home, to maintain desensitization. The maintenance 
phase is often followed by OFC to assess sustained unresponsiveness (Varshney et al., 
2011).  
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Figure 1: OIT Study Design. This time course outlines the phases of oral immunotherapy for 
one particular study, an investigation of the efficacy and safety of peanut OIT. The initial 
escalation phase was not included in this study. The arrows indicate a double-blind placebo-
controlled oral food challenge. Original image from: Michaud et al., 2015. 
 
OIT Variations  
Variations of OIT include modifications in procedure, such as timing between 
doses, phase length, or setting of the build-up phase (home vs. clinic). Additional studies 
have evaluated the effects of OIT for multiple food allergens and have combined OIT 
with probiotic and asthma medication administration. 
A study performed by Begín (et al., 2014) concluded that multiple-allergen OIT is 
both relatively safe and a feasible option for patients with multiple food allergies. 
Another investigation focused on the effect of multiple-allergen OIT on health-related 
quality of life found that multiple-allergen OIT improves health-related quality of life and 
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may relieve some of the psychosocial and economic burden imposed by a food allergy 
(Otani et al., 2014). More studies are needed to determine the efficacy and safety profile 
of multiple-allergen OIT. 
 A recent study examined the effects of peanut OIT combined with a probiotic, 
with the hypothesis that the combination of allergen protein and bacterial adjuvant would 
increase sustained unresponsiveness to peanut protein (Tang et al., 2015). Although the 
coadministration of probiotics was effective in inducing sustained unresponsiveness, 
further studies are required to conclusively attribute desensitization to the probiotics. 
 Clinical studies investigating the effect of omalizumab, a monoclonal antibody to 
IgE commonly used to treat asthma, on OIT have also been performed. In a trial 
involving multiple food allergens, omalizumab was administered to patients eight weeks 
prior to and eight weeks following a “rush OIT” (Bégin et al., 2014). Rush OIT follows a 
procedure similar to conventional OIT trials but involves a rapid increase in allergen 
dosing. This study found that administration of omalizumab before and after multiple-
allergen rush OIT facilitated rapid desensitization. A second omalizumab OIT study was 
performed with participants allergic to cow’s milk (Wood et al., 2015). The addition of 
omalizumab significantly decreased adverse reactions during OIT escalation but did not 
significantly improve desensitization or sustained unresponsiveness. 
 
OIT Results  
The majority of OIT studies have yielded positive results, though these studies 
have not used consistent outcome measures (Trendelenburg et al., 2014). Sustained 
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unresponsiveness to an allergen has been demonstrated in multiple studies, including 
clinical trials for peanut and egg allergies (Vickery et al., 2014; Burks et al., 2012). One 
study found that peanut OIT decreased subjects’ peanut-specific immune response and 
that 50% of subjects were able to successfully integrate peanuts into their regular diet 
(Vickery et al., 2014). 
 A review of multiple OIT studies found that after therapy, 61%-100% of 
participants achieved a 5- to over 1,000-fold increase in their maximum tolerated allergen 
doses (Trendelenburg et al., 2014). However, further studies are needed to determine the 
effect of OIT on long-term tolerance outcomes.  
 
OIT Side Effects 
OIT is associated with a number of acute and long-term adverse events (AEs), 
including anaphylaxis (Thyagarajan et al., 2010). Although many clinical trials have 
noted severe AEs associated with OIT, different grading systems have been used to 
define severity (Trendelenburg et al., 2014). Compared with SLIT and EPIT, OIT is 
associated with the most frequent acute AEs, such as abdominal pain and vomiting.  
Long term, OIT has also been associated with new-onset eosinophilic esophagitis 
(EOE) in 2.7% of OIT participants (Lucendo et al., 2014). EOE is an inflammatory 
condition in which large numbers of eosinophils collect within the esophagus (American 
Academy of Allergy, Asthma, & Immunology, 2016). Children with EOE often 
experience dysphagia, food impaction, and gastroesophageal reflux disease-like 
symptoms, which include heartburn, chest pain, and regurgitation (Furuta et al., 2007). 
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Further symptoms include failure to thrive and diarrhea. Diagnosis of EOE requires 
endoscopy and biopsy of esophageal tissue. EOE is a chronic condition with no known 
treatment, though glucocorticoids and proton pump inhibitors have been found to 
alleviate some symptoms.  
 
Sublingual Immunotherapy (SLIT) 
SLIT is fairly similar to OIT in terms of procedure. During SLIT, the patient’s 
allergen protein is dissolved in a liquid. Patients administer the diluted allergen with a 
dropper under their tongue, wait for one to two minutes, and then swallow the solution 
(Calderon et al., 2012). In some variations, the patients spit out the allergen solution (Cox 
et al., 2006). Like OIT, this therapy begins with a relatively low allergen dose and is 
repeated over a period of time using increasing doses. SLIT trials have had greater 
discrepancies in dosing frequency than OIT trials. Administration of the allergen protein 
can vary from daily to every few days, and an optimal rate of dosing has not been 
established. There is also considerable variation in total procedure time, which largely 
depends on the allergen. 
A potential benefit of SLIT is that the allergen proteins are directly absorbed by 
the oral mucosa (Novak et al., 2011); the proteins bypass gastric digestion, which may 
reduce gastrointestinal anaphylactic symptoms (Narisety et al., 2012). In addition, the 
amount of allergen protein used as the maintenance dose in SLIT clinical trials is 
generally much smaller than the amount used in OIT trials (usually 2500 mg), and this 
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reduced dose may account for the lower incidence of AEs (Chin et al., 2013; Jones et al., 
2014). 
 
SLIT Results 
A review of SLIT clinical trials reported that in 14 of 39 trials (35%) there was 
significant improvement in both symptoms and amount of anti-allergic medications 
needed by participants after one year, compared with those in a placebo or randomized 
control group (Cox et al., 2006). In the long-term follow-up of a randomized multicenter 
trial of peanut SLIT, 98% of peanut protein doses were tolerated after 2 years of daily 
SLIT therapy, with significantly decreased immunologic activity (Burks et al., 2015). The 
dose of peanut protein given was a 10-fold increase from baseline threshold. There were 
no AEs reported with the exception of oropharyngeal symptoms, and epinephrine was not 
administered to any of the study participants. By the end of the third year, however, over 
50% of participants had discontinued daily therapy and only 10.8% of participants 
remained fully desensitized to the peanut protein.  
 A study by Fleischer et al. (2013) found that the majority of subjects reached a 
modest level of desensitization after peanut SLIT. This study also demonstrated that 
patients who participated in SLIT for a longer duration of time were able to consume 
significantly higher doses of allergen. However, SLIT has been less effective than OIT in 
clinical trials measuring increase in threshold and number of desensitized patients 
(Trendelenburg et al., 2014).  
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SLIT Side Effects 
One review found that AEs associated with SLIT were mostly local and mild 
(e.g., oropharyngeal symptoms) (Trendelenburg et al., 2014). Although there have been 
reports suggesting the development of EOE in predisposed individuals after participation 
in SLIT clinical trials for pollen, no studies have confirmed a causal relationship 
(Miehlke et al., 2013). 
A study that investigated SLIT for the treatment of peanut allergy reported that 
63.1% of participants had no AEs after seven weeks of immunotherapy (Fleischer et al, 
2013). Another study comparing the safety and efficacy of SLIT and OIT demonstrated 
that although the rates of AEs were comparable between SLIT and OIT, OIT participants 
experienced more systemic reactions (Figure 2) (Keet et al., 2012). For this reason, SLIT 
may be considered as an alternative to OIT for severely allergic patients at high risk for 
anaphylaxis (Trendelenburg et al. 2014). However, further studies are necessary to 
effectively compare the safety profiles of OIT and SLIT. 
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Figure 2: Study Design Comparing the Safety and Efficacy of SLIT and OIT. This study, 
which investigated the treatment of cow’s milk allergy, included both SLIT and OIT arms. The 
study found that while SLIT produces less systemic reactions in participants, it is less effective 
for allergy desensitization. Original image from: Keet et al., 2012. 
 
Epicutaneous Immunotherapy (EPIT) 
EPIT is a relatively new therapy compared to OIT and SLIT and is still in 
developmental stages. Unlike OIT and SLIT, EPIT involves continuous exposure to an 
allergen, which is absorbed locally through the skin (DBV Technologies, 2016). Patients 
participating in EPIT clinical trials apply a 4x4-centimeter adhesive patch coated with 
allergen either between the shoulder blades or on the inside of the upper arm. The patch 
contains a layer of dry allergen at its center, with a “condensation chamber” between the 
skin and the center of the patch (Figure 3) (DBV Technologies, 2016). This chamber 
allows water to accumulate, solubilizing the dry allergen and allowing it to pass into the 
epidermis. Because EPIT directly targets lymph nodes by way of Langerhans cells in the 
epidermis, there is no systemic exposure to the allergen, thus lessening the risk of 
systemic reactions (Jones et al., 2014). This allows patches to be administered at home 
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without clinical supervision. A common study protocol involves applying a patch once 
every week and leaving it in place for 48 hours (Mondoulet et al., 2011). 
 
 
Figure 3: EPIT Mechanism of Action. This diagram illustrates the different components of the 
patch, including the dry allergen layer and the condensation chamber. The figure also includes 
Langerhans cells in the epidermis, which are targeted by EPIT. Original image from: DBV 
Technologies, 2016. 
 
EPIT Results 
A study using mice test subjects by Mondoulet (et al., 2012) found that allergen-
specific EPIT improved gastrointestinal symptoms induced by sustained oral exposure to 
the peanut allergen. Although multiple animal studies have demonstrated efficacy with 
EPIT, few human studies have been performed (Jones et al., 2014). The few published 
studies utilizing human subjects have reported mixed results.  
A recent clinical trial measured desensitization in peanut-allergic children before 
and after 18 months of EPIT. They found an increase in desensitization in 40% of 
patients exposed to EPIT (DuPont et al., 2014). A follow-up investigation reported that 
one child maintained desensitization a year after discontinuing EPIT (DBV Technologies, 
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2016). Conversely, a clinical pilot trial to test the effects of EPIT on children allergic to 
cow’s milk showed no significant increase in tolerance after three months (Senti et al., 
2014).  
 
EPIT Side Effects 
EPIT is generally well tolerated by participants and has a low incidence of severe 
AEs, including anaphylaxis (Senti et al., 2014). Localized eczematous skin reactions are 
commonly reported at the application site, with symptoms typically persisting for several 
days (Jones et al., 2014). However, more studies are required to thoroughly understand 
the effects associated with EPIT. 
 
Specific Aims and Objectives 
This pilot study aims to identify specific factors influencing the therapy 
preferences of parents with food-allergic children. The results may be used to inform the 
further development of the previously mentioned investigative therapies (OIT, SLIT, and 
EPIT), as well as potential novel therapies.  
 
The objectives of this pilot study are to: 
(1) Develop an online survey that will effectively discern parental preferences for 
food allergy therapy and the reasoning behind them; 
(2) Administer this survey to parents of food-allergic children via social media 
platforms and food allergy organizations; and  
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 (3) Identify themes among parent responses. 
 
This pilot study hypothesizes that: 
(1) Although parental preference with regard to specific immunotherapies is 
influenced by a variety of factors, the most common factor reported by parents 
is the safety profile of the therapy; and 
(2) Parental preferences with regard to desired outcomes of immunotherapy 
clinical trials vary by specific allergen(s). 
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METHODS 
 
This study was approved as exempt by the Institutional Review Board (IRB) of 
Northwestern University in Chicago, IL. The study involved a cross-sectional survey 
administered electronically to parents of food-allergic children. The survey was initially 
designed and evaluated by members of Dr. Ruchi Gupta’s research team at Northwestern 
University Feinberg School of Medicine Center for Community Health using a rapid-
cycle improvement method.  
 
Study Population and Eligibility 
Eligible participants for both cognitive interviews and survey participation were 
over the age of 18 and parents of at least one food-allergic child under 18 years of age.  
 
Cognitive Interviews 
Cognitive interviews were performed with parents of food-allergic children (n = 
6) before full administration of the survey to ensure its feasibility and comprehensibility. 
Cognitive interview participants were recruited through an electronic mailing that 
identified the purpose of the study, the aims of the study, and the participant inclusion 
criteria. Participants were provided with the contact information of a research assistant 
and the principal investigator in order to participate in the cognitive interviews. This 
electronic mailing was sent to a representative at Mothers of Children Having Allergies 
(MOCHA), a Chicago-based advocacy group, and disseminated via its electronic mailing 
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list. Consent was obtained verbally prior to the cognitive interview. A draft of the survey 
in Microsoft Word 2013 format (Microsoft Corporation, Redmond, WA) was sent to 
cognitive interview participants in advance of their interviews. A cognitive interview 
script and rubric were used to maintain consistency across all interviews (Appendix 1). 
Interviews were conducted for 30-45 minutes during which participants were asked about 
the feasibility of the survey, the clarity and difficulty of questions and answer choices, 
and the logic and flow of the survey. Participants were asked if additional questions 
pertaining to preferences for food allergy therapy should be included.  
Responses were audio recorded and then transcribed by a research assistant. 
Transcribed responses were subsequently analyzed using qualitative coding methods to 
identify common themes. A separate member of the research team coded each interview, 
and the principal investigator reviewed the data collected to ensure validity. The 
identified themes were used to revise the survey in an effort to improve its feasibility, 
comprehensibility, and flow.  
 
Survey Administration and Data Collection 
Following cognitive interviews, the revised survey (Appendix 2) was 
administered electronically to eligible parents through social media (i.e., Dr. Ruchi 
Gupta’s accounts on Facebook, SquareSpace, and Twitter), food allergy organizations 
(e.g., MOCHA, Asthma and Allergy Network [AAN], and American Foundation for 
Asthma and Allergy [AAFA]), and food allergy blogs (e.g., Grateful Foodie). The food 
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allergy organizations informed parents of this study through electronic mailing blasts and 
newsletters.  
A request to waive written consent for the survey was made and approved by 
Northwestern University’s IRB. The research team believed that not requiring 
participants to provide their names enhanced their willingness to be forthcoming in their 
responses to survey questions. In lieu of written consent, the research team provided 
detailed information about the study within the recruitment mailing and included the 
team’s contact information for use by participants with questions or comments. The 
survey was distributed between February 1, 2016 and March 7, 2016. Individual 
participants were involved in the study for approximately 20-25 minutes. 
Participant responses were collected exclusively from the survey. Participants’ 
identities and responses were kept confidential using a secure server maintained by 
Northwestern University. 
 
Survey Content 
The collected data included information regarding each child’s reported allergic 
reaction history and the family’s previous experiences with immunotherapy clinical trials. 
The data also contained parents’ thoughts on participation in immunotherapy clinical 
trials. The survey asked participants to rank their immunotherapy preferences and to 
complete a series of questions explaining their ranking. Additional information included 
each child’s age, gender, receptiveness to potential therapies, and demographic 
information.  
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Outcome Measures 
 The primary outcome was immunotherapy preference. The participants were 
asked to rank their first, second, and third choices of immunotherapy. A follow up 
question asked about participants’ reasons for selecting their first and last choices. In 
addition, if a participant’s child was already enrolled in a clinical trial, they were asked 
for the reason(s) they chose to enroll their child in that particular immunotherapy. 
 A secondary outcome measure was parent willingness to enroll their child in a 
clinical trial. This information was gathered in order to determine predictors for parents’ 
desire to pursue food allergy therapies through associations with the child’s allergy 
history and characteristics. 
 
Data Analysis 
Statistical analysis was conducted using Stata 14.0 (StataCorp, College Station, 
TX). Data from incomplete surveys were excluded from the analysis. Descriptive 
statistics were used to report demographic information (including age, gender, race, and 
household income). Descriptive statistics were also used to analyze food allergy therapy 
preferences and participants’ reasons for selecting a therapy as their first choice.  
 Chi-square tests were performed to examine associations between willingness to 
participate in a clinical trial and patient characteristics, including reported allergens, 
allergy severity, age, gender, race, ethnicity, and self-reported quality of life.  Fisher’s 
exact tests were used for comparisons with small sample sizes. The association between 
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willingness to participate in therapy trials and parent report of the allergy’s impact on fear 
and quality of life was also examined.  
!20 
RESULTS 
 
Survey Development  
Survey Length and Difficulty 
All cognitive interview participants believed that the survey length was “Just 
Right.” Five of the six cognitive interview participants described the overall difficulty of 
the survey as “Easy” or “Somewhat Easy.” One participant believed that the survey was 
“Not Hard or Easy” due to difficulty reviewing the survey draft in Microsoft Word 
format (Microsoft Corporation, Redmond, WA).  
Five of the six cognitive interview participants believed that the layout of the 
survey was easy to follow. One participant reported that “Part One” of the survey was 
difficult to navigate. 
 
Additional Answer Choices  
Cognitive interview participants believed that additional answer choices were 
needed to explain why they selected their most and least preferred immunotherapy. These 
choices incorporated considerations such as FDA approval, health care provider 
recommendation, possible long-term repercussions, and accessibility (e.g., geographic 
and scheduling availability, supervision requirements, affordability).  
 Cognitive interview participants also believed that information regarding efficacy 
and safety of the three immunotherapies was a necessary addition to their descriptions.  
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When asked, “What other treatments would you like to see made available?” 
participants requested additional information about potential treatments indicated in the 
answer choices (e.g., subcutaneous immunotherapy, vaccinations). 
 
Differences in Allergen Reporting  
In the first draft of the survey, participants were asked, “To what extent do 
you/does your child want to treat your child’s food allergy?” The answer choices 
included, “I want my child to be protected only against accidental ingestion” and “I want 
my child to be able to eat the food allergen as if they were not allergic.” Many cognitive 
interview participants had difficulty answering this question and desired an additional 
answer choice allowing a possible intermediate outcome. One participant stated that 
because their child was allergic to many foods, the answer to the question was allergen-
dependent. Another participant noted that the difference between raw egg and milk 
products and baked egg and milk products affected their response; the participant 
expected that the child would want to be able to eat baked goods as if they were not 
allergic but to be protected only against accidental ingestion for raw egg and milk 
products. 
 Because of these comments, the question was changed to “For your child’s 
(allergen) allergy, if you were to enroll your child in a clinical trial, what would be 
your/your child’s desired outcome?” This question was asked for each food that the child 
is allergic to. The response “To be able to eat limited amounts of this food with caution” 
was also included. If a participant indicated that his or her child cannot tolerate baked egg 
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or baked milk, this question was asked for both raw egg and baked egg or raw milk and 
baked milk to tease out the discrepancy. 
 
Survey Results 
Data were collected from 357 participants, with 246 surveys completed. 
Incomplete responses (n = 111) were not included in the final analysis. However, because 
participants were not required to respond to all survey questions, some demographic data 
was not reported for all 246 included participants. 
 
Demographic Characteristics 
 Of the study population, 65.7% (n = 161) of participants’ children were male and 
93.1% (n = 229) were White (Table 1). Most respondents (70.1%, n = 159) reported an 
annual household income of $100,000 or higher and most participants completing the 
survey reported having a college degree or higher (90.6%, n = 221). 
 
Table 1: Demographic Variability of Children with Food Allergy.  
Variable Frequency, % (n) 
 N = 246 
Age  
0-5 37.8 (93) 
6-11 41.9 (103) 
12-17 20.3 (50) 
Gender  
Female 33.9 (83) 
Male 65.7 (161) 
Other/Not Specified  0.4 (1) 
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Table 1 Continued: Demographic Variability of Children with Food Allergy  
Hispanic/Latino  
Yes 6.7 (16) 
No 92.5 (223) 
Not Specified 0.8 (2) 
Race/Ethnicity  
Caucasian/White 93.1 (229) 
Asian 7.7 (19) 
African American/Black 3.3 (8) 
American Indian/Native American 2.0 (5) 
Native Hawaiian/Other Pacific Islander 0.8 (2) 
Other 2.4 (6) 
Allergy  
Peanut 77.2 (190) 
Tree Nut 66.3 (163) 
Egg 39.4 (97) 
Milk 30.9 (76) 
Shellfish 16.3 (40) 
Soy 14.6 (36) 
Wheat  14.2 (35) 
Fin Fish 11.4 (28) 
Other 45.1 (111) 
Unknown 2.0 (5) 
Comorbidities   
Seasonal Allergy 56.5 (139) 
Eczema 55.7 (137) 
Pet Allergy 47.6 (117) 
Asthma 47.2 (116) 
Indoor Allergy 29.3 (72) 
Medication Allergy 12.2 (30) 
Insect Allergy 5.7 (14) 
None 8.5 (21) 
Other 6.1 (15) 
Approximate Household Income   
Less than $50,000 6.1 (14) 
$50,000 to $74,999 10.6 (24) 
$75,000 to $99,999 13.2 (30) 
$100,000 or Higher 70.1 (159) 
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Table 1 Continued: Demographic Variability of Children with Food Allergy  
Parent Highest Level of School  
High School Graduate or GED 2.9 (7) 
Some College 6.5 (16) 
College Degree or Higher 90.6 (221) 
Food Allergy Therapies Offered in Area  
Yes 31.3 (76) 
OIT 75.0 (51) 
SLIT 2.9 (2) 
EPIT 10.3 (7) 
Other 5.9 (4) 
Not Sure 5.9 (4) 
No/Not Sure 68.7 (167) 
 
Allergy History 
 The three most common food allergens found within this population were peanut 
(77.2%, n = 190), tree nut (66.3%, n = 163), and egg (39.4%, n = 97). The most common 
comorbid condition was seasonal allergy (56.5%, n = 139). 
 Seventy-four percent of participants (n = 182) reported that their children had 
experienced at least one severe allergic reaction. Additionally, 67.0% (n = 165) of 
participants reported being fearful of their child having an allergic reaction, while only 
27.6% (n = 68) of participants believed that their child was fearful of having an allergic 
reaction.  
 
Therapy Preferences 
 This study found that, of the parents surveyed, 69.5% (n = 171) ranked EPIT as 
their top choice, 22.8% (n = 56) ranked OIT as their top choice, and 7.7% (n = 19) ranked 
SLIT as their top choice (Figure 4).  
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Figure 4: Food Allergy Therapy Preference. 
 
 
The most common reason participants selected their first choice was “I feel my 
child would be safe undergoing this treatment” (62.6%, n = 154). Other factors cited 
included comfort (45.1%, n = 111), a lack of association with significant side effects 
(35.4%, n = 87), and efficacy (35.0%, n = 86) (Table 2). Twenty-one participants (8.5%) 
responded “Other.” When these participants were asked to specify “Other” reason(s) for 
their first choice, they responded with a multitude of comments, which ranged from 
financial considerations to ease of participation. 
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Table 2: Reasons for First Choice Therapy. 
Variable Frequency, % (n) 
 N = 246 
Why Did You Choose Your First Choice Therapy?  
I feel my child would be safe undergoing this treatment 62.6 (154) 
I feel comfortable giving my child this treatment 45.1 (111) 
I feel this treatment is not associated with significant side 
effects 
35.4 (87) 
I feel this treatment would be most effective for my child 35.0 (86) 
I have seen reports that this treatment yields good results 32.1 (79) 
I feel this treatment will last long-term 19.1 (47) 
Friends/Family have had a good experience with this 
treatment 
10.1 (25) 
My healthcare provider/physician recommended this 
treatment 
8.5 (21) 
Other 8.5 (21) 
I feel I do not have enough information about this treatment 7.3 (18) 
 
The most common reason participants gave for selecting their last choice therapy 
was “I do not feel my child would be safe undergoing this treatment” (28.1%, n = 69), 
with “I feel this treatment is associated with significant side effects” (24.8%, n = 61), “I 
do not feel comfortable giving my child this treatment (23.6%, n = 58), and “I do not feel 
this treatment would be most effective for my child” (19.9%, n = 49) also frequently 
reported (Table 3). Of the parents who selected “Other” (12.6%, n = 31), the most 
common reason was that the participant felt their child was too young or their child’s 
allergy was too severe to enroll them in a particular clinical trial. 
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Table 3: Reasons for Last Choice Therapy. 
Variable Frequency, % (n) 
 N = 246 
Why Did You Choose Your Last Choice Therapy?  
I do not feel my child would be safe undergoing this 
treatment 
28.1 (69) 
I feel this treatment is associated with significant side effects 24.8 (61) 
I do not feel comfortable giving my child this treatment 23.6 (58) 
I do not feel this treatment would be most effective for my 
child 
19.9 (49) 
I feel I do not have enough information about this treatment 15.0 (37) 
I have seen reports that this treatment does not yield good 
results 
12.6 (31) 
My child fears this treatment 12.6 (31) 
Other 12.6 (31) 
I feel this treatment will not last long-term 11.8 (29) 
My healthcare provider/physician recommended against this 
treatment 
6.1 (15) 
This treatment does not have FDA approval 5.3 (13) 
Friends/Family have had a bad experience with this treatment 4.1 (10) 
 
Pursuing Food Allergy Therapy 
Fifty percent of participants (n = 123) reported that if food allergy therapies were 
made publicly available, they would enroll their child in a therapy and 39.5% (n = 97) 
responded “Maybe” (Table 4). 
 
Table 4: Parent Interest in a Clinical Trial. 
Variable Frequency, % (n) 
 N = 246 
Would You Consider Enrolling Your Child in a Trial?  
Yes  50.0 (123) 
Maybe 39.5 (97) 
No 7.7 (19) 
Already Enrolled in a Trial 2.8 (7) 
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When participants were asked if their child would want to be enrolled in a clinical 
trial, 25.2% (n = 62) responded “Yes” and 41.5% (n = 102) responded “Maybe.” 
 
Table 5: Child Interest in a Clinical Trial. 
Variable Frequency, % (n) 
 N = 246 
Would Your Child Want to Participate in a Clinical Trial?  
Yes  25.2 (62) 
Maybe 41.5 (102) 
No 10.1 (25) 
Not Sure 23.2 (57) 
 
 The seven participants with children already enrolled in a clinical trial were asked 
why they enrolled their child in a trial (Table 6). Although the sample was small (n = 7), 
the most common reasons for enrolling in a clinical trial were geographic availability and 
reports that the therapy yielded good results (85.7%, n = 6). 
 
Table 6: Reasons for Enrolling Child in a Clinical Trial. 
Variable Frequency, % (n) 
 n = 7 
Why Did You Choose to Enroll Your Child in a Clinical 
Trial? 
 
I had seen reports that this treatment yields good results 85.7 (6) 
This treatment was made geographically available 85.7 (6) 
I trusted the healthcare provider offering this treatment 71.4 (5) 
I felt my child would be safe undergoing this treatment 71.4 (5) 
I felt this treatment would be most effective for my child 71.4 (5) 
I saw no other solutions for my child to life a safe and 
happy life 
71.4 (5) 
!29 
Table 6 Continued: Reasons for Enrolling Child in a Clinical Trial  
I felt comfortable giving my child this treatment 57.1 (4) 
I felt this treatment would last long-term 28.6 (2) 
I felt this treatment was not associated with significant side 
effects 
28.6 (2) 
Participating in this trial presented no scheduling issues 14.3 (1) 
Other 14.3 (1) 
Friends/Family had a good experience with this treatment 0 (0) 
This treatment was made financially available 0 (0) 
 
There were no statistically significant associations (p < 0.05) between willingness 
to participate in a clinical trial and patient characteristics, including reported allergens, 
severity of allergy, quality of life, and demographic information.  
Using a less conservative significance level of 0.10, having a child with wheat 
allergy was associated with being less willing to participate in a clinical trial (62.9% vs. 
37.1% of children with wheat allergy, p = 0.067), as were having a child with localized 
enlargement/swelling as a symptom (53.4% vs. 46.6% of children with swelling, p = 
0.056) and having a child with a comorbid pet allergy (54.5% vs. 45.6% of children with 
pet allergy, p = 0.084). Conversely, having a child with an almond allergy was associated 
with being more willing to participate in a clinical trial (71.4% vs. 28.6% of children with 
almond allergy, p = 0.055). 
 
Survey Design Feedback  
The survey recruitment mailing sent to parents contained the name and contact 
information of a member of the research team in case of questions or concerns. In 
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addition, participants were able to submit comments and questions at the end of the 
survey. 
A number of participants used the space to discuss their child’s allergy history 
and experiences with food allergy therapies. For instance, one participant found the 
survey difficult to complete due to their child having deficits in pragmatic language and 
detailed how that had affected the management of their child’s allergy. Participants also 
expanded on their opinions of specific food allergy therapies and their desires to increase 
therapy accessibility.  
Few participants had comments about specific survey questions. For example, one 
participant could not remember all of the reactions her child had experienced. Another 
participant could not define her child’s desired treatment outcome because, after 
eliminating peanuts from the child’s diet for 12 years, the child has no desire to eat 
peanuts at all.  
The biggest concern about the survey design came from representatives of a 
biopharmaceutical company, who believed that the descriptions of the three therapies 
showed bias. After reading through the survey, representatives of the company took issue 
with EPIT being described as “safely” releasing the allergen. The representatives also 
believed that the characterization of OIT seemed “unfriendly” compared to the 
descriptions of SLIT and EPIT due to the inclusion of safety and efficacy information.   
Although the comments received from survey participants were both positive and 
negative, a theme common to most feedback was a passion for food allergy research and 
an appreciation for investigators actively exploring food allergy therapy preferences. 
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DISCUSSION 
 
This survey is the first to describe the therapy preferences of parents with food-
allergic children. The survey results were also valuable in gaining an understanding the 
myriad of factors that may affect therapy preferences, as well as potential associations 
between willingness to undergo therapy and participant characteristics.  
This data is particularly important because, despite the increased prevalence of 
food allergies in children, there has not been research comparing these three 
immunotherapies in terms of patient and parent preference. Although the findings from 
studies examining OIT, SLIT, and EPIT have progressed in terms of clarifying safety 
profile and efficacy, an understanding of the needs of the patients and their families is 
crucial to the evolution of these novel therapies. This pilot study, and the survey 
developed for the purposes of this study, may be used to redesign current or develop new 
immunotherapies based on parental priorities and concerns.  
 
Food Allergy Therapy Preference  
 This pilot study demonstrated a tendency for parents to prefer EPIT to OIT and 
SLIT. The foremost reason for this preference was the safety profiles of the therapies; 
although EPIT has not been as effective as OIT in completed trials, the reduced risk of 
anaphylaxis was crucial to its appeal. 
 In the space available to provide comments, many participants reported that they 
felt uncomfortable with their child ingesting the food allergen, especially if the child was 
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not old enough to voice their discomfort or if the child’s allergy was particularly severe. 
In these cases, participants indicated that they believed that EPIT would be safer and 
more comfortable for their child. 
 
Impact on Quality of Life  
Many of the comments explaining why participants selected their first choice 
therapy centered on parental stress level and the comfort of their child. Most parents 
reported that their child’s food allergy greatly affected their daily lives and that they are 
fearful of their child having an allergic reaction. Nearly 70% of parents with children 
who had experienced a severe reaction in their lifetime were interested in pursuing a food 
allergy therapy. Further study is needed to determine if fear of a severe allergic reaction 
is a significant predictor of parent willingness to pursue therapy. 
This data underscores the significant impact of food allergies on the quality of life 
of children and their families. The findings suggest that fear and anxiety are major 
motivating factors in parents’ attempts to alleviate their children’s allergic responses 
through therapy.  
 
Limitations 
There were multiple limitations to this study. First, respondent burden was not 
taken into account when developing this survey. Many participants (n = 111) began the 
survey but did not complete it. Feedback indicated that the primary reason for participant 
drop-off was the length of the survey and the difficulty of the survey questions. Future 
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investigations may benefit from developing a shorter survey that only includes questions 
that are directly relevant to the research question. 
In addition, there is the possibility of selection bias within the survey population. 
Although the survey was distributed through a variety of social media platforms, the data 
demonstrate that 70.04% of participants had an approximate household income of 
$100,000 or higher. To combat this issue in future studies and ensure the validity of this 
survey, the protocol may be replicated with a larger sample size. It may be beneficial to 
obtain survey data through school and health care systems (e.g. Chicago Public Schools) 
rather than via recipients of food allergy network newsletters and electronic mail blasts. 
This may expand the survey data to include a lower socioeconomic sample. 
Another potential limitation was the language used to describe the three 
immunotherapies. According to survey feedback, participants believed that the inclusion 
of safety profiles in the descriptions might create bias against OIT due to the higher 
associated risk of anaphylaxis. In order to mitigate this bias, future studies may exclude 
an explanation of the immunotherapies’ efficacy and safety profiles. 
Because both symptoms and allergic reaction history were self-reported in the 
survey, there may have been misclassification or misreporting. Feedback given by 
participants also suggested that survey participants might have had difficulty 
remembering the details of their children’s reaction history. Although these data points 
were based on the participants’ memories, they were not crucial to the hypothesis of this 
study, and, therefore, do not affect the outcome. 
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Future Studies 
 Future studies performed on this topic may include a more comprehensive 
comparison of the three immunotherapies. Although studies have examined the efficacy 
and side effects of each immunotherapy separately, there has not been a clinical trial 
directly comparing the three therapies. This may give parents a better idea of which 
therapy to pursue for their child, based on their child’s health history and lifestyle. 
 Because fear and anxiety are a major concern of food-allergic children and their 
parents, it may also be beneficial to include quality of life comparisons within these trials. 
Although this study demonstrated that safety was a primary concern, parent responses 
also indicated that comfort was also a significant factor in a family’s decision to pursue 
food allergy immunotherapy.  
 
Conclusion 
The findings of this pilot study suggest that parents prefer EPIT to OIT and SLIT. 
Although efficacy and comfort are important factors when choosing an immunotherapy, 
the principal concern of participants was the safety profile of the therapy. This study also 
found that a large proportion of parents would choose to enroll their child in a food 
allergy therapy if given the opportunity, with half of the participants definitely interested 
in finding a therapy and another 40% possibly interested.  However, there was no 
significant variation in decision to pursue a clinical therapy based on food allergen, 
severity, or other patient characteristics. The data from this investigation demonstrate that 
food allergy has a substantial negative impact on the quality of life of children and their 
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families. This effect is so great that most parents participating in this study would be 
interested in enrolling their child in a potential food allergy therapy, in spite of the fact 
that the therapies are still in developmental stages.  
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APPENDIX 1 
Cognitive Interview Template 
 
STEP 1: Record start time of interview 
 
Interviewer Initials: 
Date of Interview:  
Interview Start Time: 
 
STEP 2: Administer survey; record start/stop time 
 
Survey Start Time: 
Survey End Time: 
 
STEP 3: Ask preliminary questions 
 
a. (Length) Do you feel the survey is: 
□ Too Long 
□ Just Right 
□ Too Short 
b. (Difficulty) How easy or hard do you think it was to read the survey? 
□ Hard* 
□ Somewhat Hard* 
□ Not Hard or Easy 
□ Somewhat Easy 
□ Easy 
 
*If response is Hard or Somewhat Hard, ask: 
 
What do you think made the survey hard? 
Participant Comments: 
 
How would you make the survey easier to read? 
Participant Comments: 
 
c. (Comfort) Did any questions make you feel uncomfortable? Why? 
□ Yes*  
□ No  
 
*If Yes, ask:  
 
Which questions made you uncomfortable? Why? 
Participant Comments: 
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STEP 4: Assess individual questions 
 
1. Would you be interested in enrolling your child in a clinical trial for potential food 
allergy treatment? 
o Yes 
o Maybe  
o My child is already enrolled in a clinical trial for food allergy treatment 
o No 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
Follow Up: Why did you choose to enroll your child in this clinical trial? Please mark all 
that apply  
*Only for subjects that have enrolled their child in a clinical trial (Question 1) 
□ This treatment was made available 
□ I felt my child would be safe undergoing this treatment 
!38 
□ I felt this treatment would be most effective for my child 
□ I felt comfortable giving my child this treatment 
□ Friends/family had a good experience with this treatment 
□ I had seen reports that this treatment yields good results 
□ I felt this treatment will last long-term 
□ I felt this treatment is not associated with many side effects 
□ I feel I do not have enough information about this treatment 
□ Other 
□ Additional comments 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
2. To what extent do you want to treat your child’s food allergy? 
o I want my child to be protected only against accidental ingestion 
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o I want my child to be able to eat the food allergen as if they were not 
allergic  
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
 
3. To what extent does your child want to be treated for their food allergy? 
o My child wants to be protected only against accidental ingestion 
o My child wants to be able to eat the food allergen as if they were not 
allergic 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
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*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
4. Do you think your child would want to undergo treatment? 
o Yes, my child is ready to undergo treatment 
o Maybe, my child fears treatment but would consider it 
o No, my child is not ready to undergo treatment 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
!41 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
 
5. There are currently a number of experimental therapies for food allergy being tested:  
 
Oral Immunotherapy (OIT): During OIT, patients ingest small but steadily 
increasing doses of their food allergen. The ultimate goal is to teach the person’s 
immune system to tolerate their allergen. 
Sublingual Immunotherapy (SLIT): During SLIT, patients ingest the food allergen 
under their tongue after the allergen is dissolved in a solution. Patients ingest small 
but steadily increasing doses of their food allergen. 
Epicutaneous Immunotherapy (EPIT): During EPIT, patients apply a 4x4 cm patch 
between their shoulder blades that safely and gradually exposes them to small 
amounts of their allergen through the skin. 
 
After reviewing the information provided, if you were to pursue treatment for your 
child’s food allergy/allergies, which therapy would you most prefer? Please rank the 
treatments in order of preference (1: most preferred, 3: least preferred) 
 
 1.   
2.  
3. 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
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b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
 
6. Why did you choose [insert their first choice here] as your first choice? Please mark 
all that apply: 
□ I feel my child would be safe undergoing this treatment 
□ I feel this treatment would be most effective for my child 
□ I feel comfortable giving my child this treatment 
□ Friends/family have had a good experience with this treatment 
□ I have seen reports that this treatment yields good results 
□ I feel this treatment will last long-term 
□ I feel this treatment is not associated with many side effects 
□ I feel I do not have enough information about this treatment 
□ Other 
□ Additional comments 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
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b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
7. Why did you choose [insert their last choice here] as your last choice? Please mark all 
that apply: 
□ I do not feel my child would be safe undergoing this treatment 
□ I do not feel this treatment would be most effective for my child 
□ I do not feel comfortable giving my child this treatment 
□ Friends/family have had a bad experience with this treatment 
□ I have seen reports that this treatment does not yield good results 
□ I feel this treatment will not last long-term 
□ I feel this treatment is associated with many side effects 
□ I feel I do not have enough information about this treatment 
□ Other 
□ Additional comments 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
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o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
 
8. What would you like to see in order to consider these treatments? Please mark all that 
apply: 
□ More studies demonstrating the success of these treatments 
□ For my child to be comfortable undergoing these treatments 
□ For the treatments to work long-term 
□ To understand the side effects of these treatments 
□ For treatments to be made affordable 
□ Other 
□ Additional comments 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
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*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
 
9. What other treatments would you like to see made available? 
□ Vaccinations 
□ Subcutaneous Allergen Immunotherapy (SCIT) 
□ Pills taken daily 
□ Other 
□ Additional comments 
 
a. How easy or hard do you think this question is to understand? 
o Hard* 
o Somewhat Hard* 
o Not Hard or Easy 
o Somewhat Easy 
o Easy 
 
*If response is anything other than Easy, ask: 
 
What do you think this question is asking? 
Participant Comments: 
 
b. Do you have any ideas about how to make this question easier to understand? 
o Yes* 
o No 
 
*If Yes, indicate proposed changes: 
 
Participant Comments: 
 
c. Do you have any additional comments about this question? 
o Yes* 
o No 
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*If Yes, record comments: 
 
Participant Comments: 
 
STEP 5: Ask closing questions 
 
a. Are there any questions that you think are missing from this survey? 
□ Yes* 
□ No 
 
*If Yes, ask: 
 
What questions would you ask? 
Participant Comments: 
 
b. Do you think the layout of the survey was easy to follow? 
□ Yes 
□ No* 
 
*If No, ask: 
 
What did you find hard or confusing about the layout? 
Participant Comments: 
 
c. Do you have any additional comments about this survey? 
□ Yes* 
□ No 
 
*If Yes, record comments: 
 
Participant Comments: 
 
d. If we have additional questions to ask in the future, would it be okay for study 
staff to contact you by email? 
□ Yes 
! Preferred email:  
□ No 
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APPENDIX 2 
Parental Therapy Preferences for Children With Food Allergy Survey 
Please answer the following questions to the best of your ability. All responses are 
anonymous and will not be shown to anyone outside of research personnel. 
 
1. How many of your children have a current food allergy?  
o 1 
o 2 
o 3 or more 
 
2. For how many of your children with food allergy would you like to complete this 
survey?  
o 1 
o 2 
o 3 
 
(Repeat the whole survey based on the answer to this question. Max: 3 times) 
 
Part 1: Current Food Allergies  
 
3. How old was your child when he or she was diagnosed with a food allergy? 
[Drop down numbers >1 to 17 years] 
• (If  >1 chosen) Months:  
 
4. To which food(s) is/are your child currently allergic? Please mark all that apply. 
□ Peanut 
□ Tree nut 
□ Type of tree nut: 
! ALL tree nuts 
! Almond 
! Cashew 
! Hazelnut 
! Pecan 
! Pistachio 
! Walnut 
! Other 
! Please specify: (Text box) 
□ Milk 
o Can your child tolerate baked milk products? 
• Yes 
• No 
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• I am not sure 
□ Egg 
o Can your child tolerate baked egg products? 
• Yes  
• No  
• I am not sure 
□ Shellfish (e.g., shrimp, crab, or lobster)) 
□ Fin Fish (e.g., cod, salmon, or tuna) 
□ Wheat 
□ Soy 
□ Other 
□ Please specify: (Text box) 
□ Unknown 
 
5. How many food allergic reactions has your child had in his or her LIFETIME? 
[Drop down numbers 0-30, greater than 30, I cannot recall] 
• How many reactions in your child’s LIFETIME would you consider 
severe or potentially life threatening? 
[Drop down numbers 0-30, greater than 30, I cannot recall] 
 
6. How many food allergic reactions has your child had in the PAST YEAR? 
[Drop down numbers 0-30, greater than 30, I cannot recall] 
• How many reactions in the PAST YEAR would you consider severe or 
potentially life threatening? 
[Drop down numbers 0-30, greater than 30, I cannot recall] 
 
7. What food(s) have caused your child to have a severe or life-threatening reaction? 
Please mark all that apply: 
□ Peanut 
□ Tree Nut 
□ Milk 
□ Egg 
□ Shellfish (e.g., shrimp, crab, or lobster) 
□ Fin Fish (e.g., cod, salmon, or tuna) 
□ Wheat 
□ Soy 
□ Other 
□ Unknown 
□ My child has never had a severe reaction 
 
8. What symptoms has your child had during a food allergic reaction? (All reactions – 
mild to severe) 
□ Hives or rash 
□ Itching/tingling 
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□ Swelling 
□ Trouble breathing 
□ Throat tightening 
□ Coughing 
□ Wheezing 
□ Nausea 
□ Vomiting 
□ Diarrhea  
□ Low blood pressure 
□ Fainting/passing out 
□ Fear/anxiety 
□ Feeling of impending doom/feeling that something bad is going to happen 
□ Other 
□ My child has never had a reaction 
 
Part 2: Food Allergy Therapy Preference  
 
9. How much does your child’s food allergy affect HIS or HER daily life? 
o Not at all 
o A little bit 
o Moderately  
o Very much 
o Extremely  
o Not applicable 
 
10. How much does your child’s food allergy affect YOUR daily life? 
o Not at all 
o A little bit 
o Moderately  
o Very much 
o Extremely  
o Not applicable 
             
11. How fearful is YOUR CHILD of having an allergic reaction? 
o Not at all 
o A little bit 
o Moderately  
o Very much 
o Extremely  
o Not applicable 
 
12. How fearful are YOU of your child having an allergic reaction? 
o Not at all  
o A little bit 
!50 
o Moderately 
o Very much 
o Extremely  
o Not applicable  
 
13. Desired clinical trial outcome: (Allergen only appears if selected in Question 4, both 
questions are asked for all allergens selected in Question 4) 
o For your child’s ALLERGEN allergy, if you were to enroll your child in a 
clinical trial, what would be YOUR desired outcome? 
• To be protected only against accidental ingestion 
• To be able to eat limited amounts of this food with caution 
• To be able to eat the food allergen as if they were not allergic 
o For your child’s ALLERGEN allergy, if you were to enroll your child in a 
clinical trial, what would be YOUR CHILD’S desired outcome? 
• To be protected only against accidental ingestion 
• To be able to eat limited amounts of this food with caution 
• To be able to eat the food allergen as if they were not allergic 
 
14. If clinical trials for potential food allergy treatments were publicly available, would 
you consider enrolling your child in a trial?  
Clinical trials involve exposing the subject to increasing doses of their food allergen. 
The first phase of current clinical studies is clinician-supervised, and is generally 
followed by a daily at-home maintenance phase. 
• Yes 
• Maybe 
• No  
o (Text box) 
• My child is already enrolled in a clinical trial for food allergy treatment 
o What kind of clinical trial is your child enrolled in? 
• Oral Immunotherapy  
• Sublingual Immunotherapy 
• Epicutaneous Immunotherapy 
• Other 
• Please specify: (Text box) 
o Why did you choose to enroll your child in [insert clinical trial here]? 
Please mark all that apply: 
! This treatment was made financially available 
! This treatment was made geographically available 
! Participating in this trial presented no scheduling issues 
! I trusted the healthcare provider offering this treatment 
! I felt my child would be safe undergoing this treatment 
! I felt this treatment would be most effective for my child 
! I felt comfortable giving my child this treatment 
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! Friends/family had a good experience with this treatment 
! I had seen reports that this treatment yields good results 
! I felt this treatment would last long-term 
! I felt this treatment was not associated with significant side effects 
! I saw no other solutions for my child to live a safe and happy life 
! Other:  
o Please specify: (Text box) 
! Additional Comments: (Text box) 
• My child initiated a clinical trial for food allergy treatment, but was not able to 
complete it 
o What kind of clinical trial was your child enrolled in? 
• Oral Immunotherapy  
• Sublingual Immunotherapy 
• Epicutaneous Immunotherapy 
• Other 
• Please specify: (Text box) 
o Why did you choose to enroll your child in [insert clinical trial here]? 
Please mark all that apply: 
! This treatment was made financially available 
! This treatment was made geographically available 
! Participating in this trial presented no scheduling issues 
! I trusted the healthcare provider offering this treatment 
! I felt my child would be safe undergoing this treatment 
! I felt this treatment would be most effective for my child 
! I felt comfortable giving my child this treatment 
! Friends/family had a good experience with this treatment 
! I had seen reports that this treatment yields good results 
! I felt this treatment would last long-term 
! I felt this treatment was not associated with significant side effects 
! I saw no other solutions for my child to live a safe and happy life 
! Other:  
• Please specify: (Text box) 
• Additional Comments: (Text box) 
o Why was your child unable to complete the clinical trial? Please mark all 
that apply: 
! Severe reaction/side effects 
! Financial constraints 
! Time constrains/scheduling conflicts 
! Geographical constraints 
! Eosinophilic Esophagitis (EOE) development 
! Anxiety/fear 
! Other 
• Please specify: (Text box) 
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15. Do you think your child would want to participate in a clinical trial for food allergy 
therapy? 
• Yes, my child is willing to undergo therapy 
• Maybe, my child would consider undergoing therapy 
• Why is your child hesitant to initiate treatment? 
! Time constraints/scheduling conflicts 
! Geographic constraints 
! Fear/anxiety 
! Other 
□ Please specify: (Text box) 
! Additional Comments: (Text box) 
• No, my child is not willing to undergo therapy 
• (Text box) 
• I am not sure 
 
16. For how long would you be willing to enroll your child in a clinical trial for food 
allergy therapy? 
• 4-6 months 
• 6-12 months 
• 1 year 
• 2  years 
• 3 years 
• More than 3 years 
 
17. There are currently a number of experimental therapies for food allergy being tested:  
o Oral Immunotherapy (OIT): During OIT, patients ingest steadily increasing 
doses of their food allergen (e.g. peanut powder) over a short period of time under 
the supervision of their clinician. Once patients reach a target dose amount, they 
begin a maintenance phase. This involves ingesting a daily dose of their allergen. 
Recent studies have shown that many patients become desensitized to their 
allergen after OIT but have more reactions during the “build up” phase compared 
to other treatments. 
o Sublingual Immunotherapy (SLIT): During SLIT, the patient’s allergen is 
dissolved in a liquid. This liquid is then held under the patient’s tongue and 
swallowed. Patients begin by ingesting a small dose, which is gradually increased. 
Although the results of these studies have not been as successful compared to 
OIT, patients tend to have fewer reactions. 
o Epicutaneous Immunotherapy (EPIT): EPIT is a new therapy, during which 
the patient applies a 4x4 cm patch, typically on the back for children and on the 
inside of the upper arm for adolescents. This patch safely and gradually releases 
small amounts of their allergen through the skin. Although this technology is still 
in development, studies have shown that it presents less risk of reaction than oral 
ingestion. 
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After reviewing the information provided, if you were to pursue treatment for your 
child’s food allergy/allergies, which therapy would you most prefer? Please rank the 
treatments in order of preference (1: most preferred, 3: least preferred) 
1. (Drop down: treatment options) 
2. (Drop down: treatment options) 
3. (Drop down: treatment options) 
  
 
18. Why did you choose [insert their first choice here] as your first choice? Please mark 
all that apply: 
□ I feel my child would be safe undergoing this treatment 
□ I feel this treatment would be most effective for my child 
□ I feel comfortable giving my child this treatment 
□ Friends/family have had a good experience with this treatment 
□ I have seen reports that this treatment yields good results 
o Where did you find this information? Please mark all that apply: 
! Advocacy groups 
! Food allergy blogs 
! Physician 
! Manufacturer website 
! Research manuscript 
! Social media 
! Other 
• Please specify: (Text box) 
! Additional Comments: (Text box) 
□ I feel this treatment will last long-term 
□ I feel this treatment is not associated with significant side effects 
□ My healthcare provider/physician recommended this treatment 
□ I feel I do not have enough information about this treatment  
□ Other:  
o Please specify: (Text box) 
□ Additional Comments: (Text box) 
 
19. Why did you choose [insert their third choice here] as your last choice? Please mark 
all that apply: 
□ I do not feel my child would be safe undergoing this treatment 
□ I do not believe this treatment would be effective for my child 
□ I do not feel comfortable giving my child this treatment 
□ Friends/family have had a bad experience with this treatment 
□ I have seen reports that this treatment does not yield good results 
o Where did you find this information? Please mark all that apply: 
! Advocacy groups 
! Food allergy blogs 
! Physician 
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! Manufacturer website 
! Research manuscript 
! Social media 
! Other 
• Please specify: (Text box) 
! Additional Comments: (Text box) 
□ I feel this treatment will not last long-term 
□ I feel this treatment is associated with significant side effects 
□ My healthcare provider/physician recommended against this treatment 
□ There may be possible long-term issues associated with this treatment (i.e. 
EOE, cancer) 
□ This treatment does not have FDA approval 
□ My child fears this treatment 
□ I feel I do not have enough information about this treatment 
□ Other: 
o Please specify: (Text box) 
□ Additional Comments: (Text box) 
 
20. What would you like to see in order to consider these treatments for your child? 
Please mark all that apply: 
□ More studies demonstrating the success of these treatments  
□ For my child to be comfortable undergoing these treatments 
□ For these treatments to work long-term 
□ To understand the potential side effects of these treatments  
□ For these treatments to be made accessible 
• What would you like treatment providers to consider? Please mark all 
that apply: 
□ Parental availability/supervision requirements 
□ Geographic availability 
□ Financial availability 
□ Scheduling flexibility 
□ Hygiene requirements 
□ FDA approval for these treatments 
□ Allergist recommendation  
□ Pediatrician recommendation  
□ Other clinician recommendation 
! Please specify: (Text box) 
□ Other: 
! Please specify: (Text box) 
□ Anything else that you would like to see?: (Text box) 
 
21. What other treatments would you like to see made available? Please mark all that 
apply: 
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□ Vaccination: Vaccinations are periodic but limited injections that teach the 
patient’s immune system to recognize their allergen. 
□ Subcutaneous Immunotherapy (SCIT): SCIT involves the injection of the 
patient’s allergen under the skin. It consists of weekly injections under the 
supervision of a clinician during the build up phase, followed by monthly 
maintenance injections over a period of years. 
□ Pills/oral medications 
□ Traditional Chinese herbal therapy 
□ Probiotics 
□ Other:  
! Please specify: (Text box) 
□ Additional Comments: (Text box) 
 
Part 3: Demographic Information  
 
22. What is the child’s age 
[Drop down numbers >1 to 17 years] 
 
23. What is the child’s gender? 
• Male 
• Female  
• Other/would not like to report 
 
24.  Is the child Hispanic or Latino? 
• Yes 
• No  
• Unknown  
• Not specified 
 
25. What is the child’s race/ethnicity? (Please select all that apply) 
□ Black/African American 
□ White 
□ Asian 
□ American Indian/Alaska Native 
□ Native Hawaiian or other Pacific Islander 
□ Other  
! Please specify: (Text box) 
 
26. Does your child have any of the following medical conditions? Please mark all that 
apply: 
□ Asthma 
□ Eczema 
□ Seasonal Allergy 
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□ Indoor Allergy 
□ Pet Allergy 
□ Insect Allergy 
□ Medication Allergy 
□ None  
□ Other  
o Please specify: (Text box) 
 
27. What is your relationship to the child? 
• Mother 
• Father 
• Grandparent 
• Other 
o Please specify: (Text box) 
 
28. What is the highest grade of school you have completed?   
• Some Secondary School (9th grade and above) 
• High School Graduate or GED 
• Some College 
• College degree (e.g., BA, BS, BFA) 
• Master’s degree (e.g., MA,MS, MFA, MBA, MPH) 
• Doctoral degree (e.g., PhD, MD, JD, PharmD) 
 
29. What was your approximate household income last year (including government 
assistance)? 
• Less than $50,000 
• $50,000 to $74,999 
• $75,000 to $99,999 
• $100,000 or higher 
 
30. What are the first 3 digits of your current zip code?  
[Fill in numbers] 
 
31. Do you know if there are any food allergy clinical therapies being offered in your 
area? 
• Yes 
o What therapy is being offered? Please mark all that apply. 
! Oral immunotherapy 
! Sublingual immunotherapy 
! Epicutaneous immunotherapy 
! Other 
• Please specify: (Text box) 
! I am not sure 
• No 
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• I am not sure  
 
Do you have any additional comments?  
• (Paragraph box) 
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